Secretion of Acetylated Amino Acids by Drug-Induced Cancer Cells: Perspectives on Metabolic-Epigenetic Alterations

References

• Levine AJ , Puzio-KuterAM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science330(6009), 1340–1344 (2010).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144, 646–74 (2011).
   PubMed Web of Science ®Google Scholar
• Lyssiotis CA , KimmelmanAC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol.27, 863–75 (2017).
   PubMed Web of Science ®Google Scholar
• Crosby D , BhatiaS , BrindleKMet al. Early diagnosis of cancer. Science375(6586), eaay9040 (2022).
   PubMed Web of Science ®Google Scholar
• Mohammad RM , MuqbilI , LoweLet al. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol.Suppl.(0), S78–S103 (2015).
   Google Scholar
• Pistritto G , TrisciuoglioD , CeciCet al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY).8(4), 603–19 (2016).
   PubMedGoogle Scholar
• Mansoori B , MohammadiA , DavudianSet al. The different mechanisms of cancer drug resistance: a brief review. Adv. Pharm. Bull.7(3), 339–348 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao Y , ButlerEB , TanM. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis.4(3), e532 (2013).
   PubMed Web of Science ®Google Scholar
• Wishart DS . Metabolomics for investigating physiological and pathophysiological processes. Physiol. Rev.99(4), 1819–1875 (2019).
   PubMed Web of Science ®Google Scholar
• Chen X , ChenS , YuD. Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance. Metabolites10(7), 289 (2020).
   PubMed Web of Science ®Google Scholar
• Desbats MA , GiacominiI , Prayer-GalettiTet al. Metabolic plasticity in chemotherapy resistance. Front. Oncol.10, 281 (2020).
   PubMed Web of Science ®Google Scholar
• Schmidt DR , PatelR , KirschDGet al. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J. Clin.71(4), 333–358 (2021).
   PubMed Web of Science ®Google Scholar
• Morrison AJ . Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS J.289(5), 1302–1314 (2022).
   PubMed Web of Science ®Google Scholar
• Raskov H , GaggarS , TajikAet al. Metabolic switch in cancer – survival of the fittest. Eur. J. Cancer.180, 30–51 (2023).
   PubMed Web of Science ®Google Scholar
• Baslow MH . Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain’s ‘operating system’: how NAA metabolism supports meaningful intercellular frequency-encoded communications. Amino Acids39(5), 1139–45 (2010).
   PubMed Web of Science ®Google Scholar
• Lieu EL , NguyenT , RhyneSet al. Amino acids in cancer. Exp. Mol. Med.52(1), 15–30 (2020).
   PubMed Web of Science ®Google Scholar
• Vettore L , WestbrookRL , TennantDA. New aspects of amino acid metabolism in cancer. Br. J. Cancer.122(2), 150–156 (2020).
   PubMed Web of Science ®Google Scholar
• Ohnari H , SekiyaM , NaruEet al. Amino acids and their N-acetylated derivatives maintain the skin’s barrier function. Chem. Pharm. Bull. (Tokyo)69(7), 652–660 (2021).
   PubMed Web of Science ®Google Scholar
• Wei Z , LiuX , ChengCet al. Metabolism of amino acids in cancer. Front. Cell Dev. Biol.8, 603837 (2021).
   PubMed Web of Science ®Google Scholar
• Yoo HC , HanJM. Amino acid metabolism in cancer drug resistance. Cells11(1), 140 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang C , QuinonesA , LeA. Metabolic reservoir cycles in cancer. Semin. Cancer Biol.86(Pt 3), 180–188 (2022).
   PubMedGoogle Scholar
• Li X , ZhangHS. Amino acid metabolism, redox balance and epigenetic regulation in cancer. FEBS J. doi: 10.1111/febs.16803 (2023) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Zhong Y , OnukiJ , YamasakiTet al. Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma. Carcinogenesis30(1), 158–64 (2009).
   PubMed Web of Science ®Google Scholar
• Hong CS , GrahamNA , GuWet al. MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep.14(7), 1590–1601 (2016).
   PubMed Web of Science ®Google Scholar
• Felmlee MA , JonesRS , Rodriguez-CruzVet al. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol. Rev.72(2), 466–485 (2020).
   PubMed Web of Science ®Google Scholar
• Churchill GC , StruppM , FactorCet al. Acetylation turns leucine into a drug by membrane transporter switching. Sci. Rep.11(1), 15812 (2021).
   PubMed Web of Science ®Google Scholar
• Wang Y , QinL , ChenWet al. Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1. Eur. J. Med. Chem.226, 113806 (2021).
   PubMed Web of Science ®Google Scholar
• Šikić K , PetersTMA , MarušićEet al. Abnormal concentrations of acetylated amino acids in cerebrospinal fluid in acetyl-CoA transporter deficiency. J. Inherit. Metab. Dis.45(6), 1048–1058 (2022).
   PubMed Web of Science ®Google Scholar
• Nishikubo K , OhgakiR , LiuXet al. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells. Cancer Cell Int.23(1), 116 (2023).
   PubMed Web of Science ®Google Scholar
• Palacín M , KanaiY. The ancillary proteins of HATs: SLC3 family of amino acid transporters. Pflugers Arch.447(5), 490–4 (2004).
   PubMed Web of Science ®Google Scholar
• Verrey F , ClossEI , WagnerCAet al. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch.447(5), 532–42 (2004).
   PubMed Web of Science ®Google Scholar
• Perland E , FredrikssonR. Classification systems of secondary active transporters. Trends Pharmacol. Sci.38(3), 305–315 (2017).
   PubMed Web of Science ®Google Scholar
• Peleg S , FellerC , LadurnerAGet al. The metabolic impact on histone acetylation and transcription in ageing. Trends Biochem. Sci.41(8), 700–711 (2016).
   PubMed Web of Science ®Google Scholar
• Audia JE , CampbellRM. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol.8(4), a019521 (2016).
   PubMed Web of Science ®Google Scholar
• Cheng Y , HeC , WangMet al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target Ther.4, 62 (2019).
   PubMed Web of Science ®Google Scholar
• Galdieri L , ChangJ , MehrotraSet al. Yeast phospholipase C is required for normal acetyl-CoA homeostasis and global histone acetylation. J. Biol. Chem.288(39), 27986–98 (2013).
   PubMed Web of Science ®Google Scholar
• Mehrotra S , GaldieriL , ZhangTet al. Histone hypoacetylation-activated genes are repressed by acetyl-CoA- and chromatin-mediated mechanism. Biochim. Biophys. Acta.1839(9), 751–63 (2014).
   PubMed Web of Science ®Google Scholar
• Shi L , TuBP. Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr. Opin. Cell Biol.33, 125–31 (2015).
   PubMed Web of Science ®Google Scholar
• Contreras-Sanzón E , Prado-GarciaH , Romero-GarciaSet al. Histone deacetylases modulate resistance to the therapy in lung cancer. Front. Genet.13, 960263 (2022).
   PubMed Web of Science ®Google Scholar
• Neganova ME , KlochkovSG , AleksandrovaYRet al. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin. Cancer Biol.83, 452–471 (2022).
   PubMed Web of Science ®Google Scholar
• Shanmukha KD , PaluvaiH , LomadaSKet al. Histone deacetylase (HDACs) inhibitors: clinical applications. Prog. Mol. Biol. Transl. Sci.198, 119–152 (2023).
   PubMedGoogle Scholar
• McBrian MA , BehbahanIS , FerrariRet al. Histone acetylation regulates intracellular pH. Mol. Cell.49(2), 310–21 (2013).
   PubMed Web of Science ®Google Scholar
• Flinck M , KramerSH , PedersenSF. Roles of pH in control of cell proliferation. Acta Physiol (Oxf).223(3), e13068 (2018).
   PubMed Web of Science ®Google Scholar
• Van Wauwe J , Van NyenG , CoeneMCet al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol. Exp. Ther.261(2), 773–9 (1992).
   PubMed Web of Science ®Google Scholar
• Nie D , LambertiM , ZacharekAet al. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun.267(1), 245–51 (2000).
   PubMed Web of Science ®Google Scholar
• Yoon WH , JungYJ , KimTDet al. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin. Cancer Res.10(13), 4517–26 (2004).
   PubMed Web of Science ®Google Scholar
• Patel NJ , KaruturiR , Al-HoraniRAet al. Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells. ACS Chem. Biol.9(8), 1826–33 (2014).
   PubMed Web of Science ®Google Scholar
• Galdieri L , GatlaH , VancurovaIet al. Activation of AMP-activated protein kinase by metformin induces protein acetylation in prostate and ovarian cancer cells. J. Biol. Chem.291(48), 25154–25166 (2016).
   PubMed Web of Science ®Google Scholar
• Rupiani S , GuidottiL , ManerbaMet al. Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A. Org. Biomol. Chem.4(46), 10981–10987 (2016).
   Google Scholar
• S Soderquist R , EastmanA. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther.5(9), 2011–7 (2016).
   Google Scholar
• Miller KD , PniewskiK , PerryCEet al. Targeting ACSS2 with a transition-state mimetic inhibits triple-negative breast cancer growth. Cancer Res.81(5), 1252–1264 (2021).
   PubMed Web of Science ®Google Scholar
• Lemberg KM , GoriSS , TsukamotoTet al. Clinical development of metabolic inhibitors for oncology. J. Clin. Invest.132(1), e148550 (2022).
   PubMed Web of Science ®Google Scholar
• Morla S , RavikumarO , O’HaraCet al. Designing synthetic, sulfated glycosaminoglycan mimetics that are orally bioavailable and exhibiting in vivo anticancer activity. J. Med. Chem.66(2), 1321–1338 (2023).
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R , HomayouniTS , BaluchNet al. Combination therapy in combating cancer. Oncotarget8(23), 38022–38043 (2017).
   PubMedGoogle Scholar
• Palmer AC , SorgerPK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell171(7), 1678–1691.e13 (2017).
   PubMed Web of Science ®Google Scholar
• Kowalski JP , McDonaldMG , PelletierRDet al. Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome P450 4Z1. J. Med. Chem.63(9), 4824–4836 (2020).
   PubMed Web of Science ®Google Scholar
• Zhong L , LiY , XiongLet al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Target Ther.6(1), 201 (2021).
   PubMed Web of Science ®Google Scholar
• Plana D , PalmerAC , SorgerPK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov.12(3), 606–624 (2022).
   PubMed Web of Science ®Google Scholar
• Stine ZE , SchugZT , SalvinoJMet al. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov.21(2), 141–162 (2022).
   PubMed Web of Science ®Google Scholar
• Duan C , YuM , XuJet al. Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed. Pharmacother.162, 114643 (2023).
   PubMed Web of Science ®Google Scholar